Status:
COMPLETED
Tolerability of Grazax in Patients With Hayfever in Real Life Settings
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Allergic Rhinoconjunctivitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess the safety profile of specific immunotherapy with Grazax for three consecutive grass pollen seasons.
Detailed Description
To assess the safety profile with Grazax according to the presence or not of polysensitization and/or asthma at enrollment
Eligibility Criteria
Inclusion
- History of grass pollen allergy
- Positive skin prick-test and/or positive specific IgE to grass
Exclusion
- Severe, unstable or uncontrolled asthma (FEV1\<70% of predicted value)
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
628 Patients enrolled
Trial Details
Trial ID
NCT01433510
Start Date
November 1 2007
End Date
December 1 2010
Last Update
May 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire
Nantes, France, 44000